RxDoctor Payments Data

Mikhail Regelman, MD

Urology · Woodbury, MNNPI 1891015384

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (34.5%), education and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Intuitive Surgical at 37.7% of the total.

$9,968in general payments, 2019–2025

Across 140 payments — averaging $71.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Sanofi$2K
  • Blue Earth Diagnostics$934
  • Sumitomo Pharma America, Inc.$502
  • Urovant Sciences Inc$484
  • Dendreon Pharmaceuticals LLC$394
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$2,92729%
  • Travel & lodging$6066%
  • Food & beverage$3,43534%
  • Education$3,00030%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,968 in reported general payments places this provider in the 85th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$227,169
Medicare patients
458
Services billed
1,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$186,695
MyrbetriqMirabegron122$98,639
GemtesaVibegron74$57,202
Tamsulosin Hcl624$11,400
Solifenacin Succinate138$6,121
Tadalafil41$6,003
Finasteride337$4,784
Alfuzosin Hcl ErAlfuzosin Hcl130$3,188
Dutasteride25$1,778
Silodosin17$1,441
Oxybutynin Chloride ErOxybutynin Chloride36$1,194
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav89$710
Cephalexin90$605
Tolterodine Tartrate ErTolterodine Tartrate13$535
Imipramine Hcl12$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$108$285,334135 claims
Sumitomo Pharma America, Inc.Gemtesa$502$57,20274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 urology providers in Minnesota.

Other urology in Woodbury

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →